July 12, 2021
Researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.
May 16, 2022
COVID-19, MIS-C and KD all share a similar underlying mechanism involving the over-activation of particular inflammatory pathways, UC San Diego study shows. Findings support novel drug targets for MIS-C.
August 31, 2021
UC San Diego researchers developed first-of-their-kind lung organoids that include all cell types that make up the organ, allowing for “Phase 0” testing of new treatments for respiratory infections such as COVID-19.
February 10, 2020
UC San Diego researchers use 3D human gut organoids to reveal the molecular system that keeps intestinal linings sealed, demonstrate how the system breaks down and how it can be strengthened with the diabetes drug metformin.
June 11, 2021
UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.
May 18, 2023
Across disciplines and specialties, from cells to systems, artificial intelligence is on its way to altering how we understand and treat disease.
July 21, 2021
UC San Diego is one of six universities invited to participate in the Wu Tsai Human Performance Alliance, a scientific collaboration that aims to transform human health on a global scale through the discovery and translation of the biological principles underlying human performance.
November 12, 2020
…fatty liver disease (NAFLD). Pradipta Ghosh and team discovered that a molecule called GIV acts as a brake on macrophages, keeping them in check. The researchers can also mimic GIV as a means to reduce inflammation in cases where it’s detrimental, such as in sepsis and colitis. Samara Reck-Peterson, Andres…
January 31, 2023
The evolution of clinical trials is accelerating, driven by emerging technologies, social imperatives and the next public health crisis.
